Spots Global Cancer Trial Database for bortezomib
Every month we try and update this database with for bortezomib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) | NCT00473590 | Multiple Myelom... | Bevacizumab Bortezomib placebo | 18 Years - | Genentech, Inc. | |
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | NCT00667641 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Prostate Cancer Unspecified Adu... | bortezomib paclitaxel | 18 Years - | Rutgers, The State University of New Jersey | |
| Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | NCT00798720 | Carcinoma, Non ... | vorinostat bortezomib | 18 Years - | University of Wisconsin, Madison | |
| Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | NCT04091126 | Multiple Myelom... | Belantamab mafo... Bortezomib Lenalidomide Dexamethasone | 18 Years - | GlaxoSmithKline | |
| Quality of Life in Multiple Myeloma Patients Treated With Bortezomib | NCT01021592 | Multiple Myelom... | bortezomib | 18 Years - | Janssen Korea, Ltd., Korea | |
| Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) | NCT03643549 | Glioblastoma | Bortezomib and ... Bortezomib and ... | 18 Years - | Haukeland University Hospital | |
| Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer | NCT00714246 | Non Small Cell ... | Bortezomib Carboplatin Docetaxel | 18 Years - 90 Years | Milton S. Hershey Medical Center | |
| Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | NCT00066352 | Bladder Cancer Transitional Ce... | bortezomib | 18 Years - | University Health Network, Toronto | |
| Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia | NCT00777738 | Waldenstrom Mac... | BORTEZOMIB | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | NCT01329289 | Multiple Myelom... Multiple Myelom... | SOM230 Bortezomib Dexamethasone | 18 Years - | University of Pittsburgh | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | NCT05804032 | Multiple Myelom... | Isatuximab Isatuximab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | NCT00903968 | Multiple Myelom... | Plerixafor bortezomib Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00262860 | Lymphoma | bortezomib gemcitabine hyd... | 18 Years - 120 Years | University of Rochester | |
| Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) | NCT02955810 | Multiple Myelom... | Daratumumab Cyclophosphamid... Bortezomib Dexamethasone | 18 Years - 70 Years | National University of Ireland, Galway, Ireland | |
| Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma | NCT00538187 | Adult Non-Hodgk... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... | obatoclax mesyl... bortezomib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT01074411 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Brenner... Ovarian Clear C... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Transit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Undifferentiate... Undifferentiate... | Bortezomib Carboplatin Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | NCT00006184 | Multiple Myelom... | Myeloma Immunog... Bortezomib Cyclophosphamid... Cyclosporine Doxorubicin hyd... Etoposide Fludarabine pho... Prednisone Vincristine Sul... Methotrexate GMCSF (granuloc... GCSF (granulocy... | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Bortezomib Plus Rituximab for EBV+ PTLD | NCT01058239 | Post-transplant... Solid Organ Tra... Stem Cell Trans... Epstein Barr Vi... | bortezomib rituximab | 18 Years - | Massachusetts General Hospital | |
| MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning | NCT00564200 | Multiple Myelom... | Bortezomib dexamethasone Fludarabine Melphalan | 18 Years - 66 Years | PETHEMA Foundation | |
| Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma | NCT00863369 | Lymphoma | rituximab bortezomib gemcitabine hyd... questionnaire a... | 18 Years - | City of Hope Medical Center | |
| Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma | NCT02840539 | Mantle Cell Lym... | Bortezomib, Cyt... | 18 Years - | Seoul National University Hospital | |
| Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT | NCT05218603 | Multiple Myelom... Non-eligible fo... | Bortezomib Daratumumab | 18 Years - | PETHEMA Foundation | |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | NCT04722146 | Multiple Myelom... | Teclistamab Daratumumab Pomalidomide Lenalidomide Bortezomib Nirogacestat | 18 Years - | Janssen Research & Development, LLC | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma | NCT01315873 | Multiple Myelom... | Bendamustine Bortezomib | 18 Years - | NYU Langone Health | |
| Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT00553644 | Recurrent Mantl... | Bortezomib Laboratory Biom... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | NCT00243035 | Refractory Mult... Stage II Multip... Stage III Multi... | bortezomib tipifarnib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma | NCT02268890 | Multiple Myelom... | Bortezomib | 20 Years - | Johnson & Johnson Taiwan Ltd | |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | NCT01381692 | Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... | Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma | NCT01902862 | Lymphoma, Folli... | Bortezomib Rituximab | 18 Years - 70 Years | Janssen-Cilag G.m.b.H | |
| Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT00265928 | Lymphoma | bortezomib rituximab antibody therap... biological ther... enzyme inhibito... monoclonal anti... | 18 Years - | National Cancer Institute (NCI) | |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | NCT01023308 | Multiple Myelom... | Panobinostat Bortezomib Dexamethasone Placebo | 18 Years - | Novartis | |
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT01266811 | Multiple Myelom... | Placebo, Velcad... Siltuximab, Vel... | 18 Years - | Centocor, Inc. | |
| Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | NCT01449344 | Mantle Cell Lym... | Rituximab High dose Ara-C Dexamethasone Bortezomib | 18 Years - | European Mantle Cell Lymphoma Network | |
| Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | NCT00334438 | Lymphoma | rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri... | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| PS-341 in Treating Patients With Metastatic Malignant Melanoma | NCT00024011 | Recurrent Melan... Stage IV Melano... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| PS-341 in Treating Patients With Metastatic Kidney Cancer | NCT00017329 | Kidney Cancer | bortezomib | - | National Cancer Institute (NCI) | |
| Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00316940 | Multiple Myelom... | bortezomib samarium Sm 153... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Temsirolimus, Topotecan, and Bortezomib | NCT00770731 | Advanced Cancer | Torisel (Temsir... Hycamtin (Topot... Velcade (Bortez... | - | M.D. Anderson Cancer Center | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00075881 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis | NCT04612582 | Immunoglobulin ... | Thalidomide Cyclophosphamid... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT00818649 | Leukemia Myelodysplastic... | bortezomib vorinostat | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma | NCT01029730 | Lymphoma | Bendamustine Bortezomib Rituximab | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma | NCT00315757 | Multiple Myelom... | Mapatumumab Mapatumumab Bortezomib | 18 Years - | Human Genome Sciences Inc. | |
| Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | NCT01332617 | Myeloma | Simvastatin,Zol... | 18 Years - | University of Louisville | |
| Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | NCT01695941 | Recurrent B-Cel... Recurrent Mantl... Refractory B-Ce... Refractory Mant... | Alisertib Bortezomib Laboratory Biom... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy | NCT01056601 | Pancreatic Canc... | Bortezomib Panobinostat | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | NCT01736943 | Acute Myelogeno... | Bortezomib Doxil | 18 Years - 80 Years | University of California, Davis | |
| A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma | NCT00636311 | Hodgkin Disease | Ifosfamide, Gem... Bortezomib + IG... | 18 Years - 65 Years | Istituto Clinico Humanitas | |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | NCT03314181 | Multiple Myelom... | Dexamethasone Daratumumab Venetoclax Bortezomib | 18 Years - | AbbVie | |
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance | NCT01647165 | Multiple Myelom... | Bortezomib Lenalidomide Dexamethasone | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma | NCT02481934 | Multiple Myelom... | NKAE cells infu... Lenalidomide Bortezomib | 20 Years - 80 Years | Hospital Universitario 12 de Octubre | |
| Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma | NCT00428142 | Lymphoma | rituximab bortezomib cyclophosphamid... prednisone vincristine sul... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | NCT00483262 | Multiple Myelom... | CCI-779 Bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | NCT02773030 | Multiple Myelom... | CC-220 Dexamethasone Daratumumab Bortezomib Carfilzomib | 18 Years - | Celgene | |
| Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma | NCT01168804 | Multiple Myelom... | bendamustine pl... | 18 Years - | Austrian Forum Against Cancer | |
| A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | NCT01599949 | Mantle Cell Lym... | Ibrutinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM | NCT04414475 | Multiple Myelom... | Selinexor Dexamethasone Bortezomib Pomalidomide | 18 Years - | Karyopharm Therapeutics Inc | |
| Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. | NCT01026701 | Multiple Myelom... | bortezomib | 18 Years - | Janssen Korea, Ltd., Korea | |
| Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00075881 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | NCT00560352 | Multiple Myelom... | Dasatinib Bortezomib Dexamethasone | 18 Years - | Bristol-Myers Squibb | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | NCT06152575 | Multiple Myelom... | Elranatamab Elotuzumab Pomalidomide Dexamethasone Bortezomib Carfilzomib | 18 Years - | Pfizer | |
| Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00425750 | Head and Neck C... | bortezomib docetaxel laboratory biom... pharmacological... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Microdose Study of Melphalan, Bortezomib and Dexamethasone | NCT02109861 | Multiple Myelom... | Melphalan Bortezomib Dexamethasone | 18 Years - | Aalborg University Hospital | |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | NCT05514990 | Recurrent Plasm... Refractory Plas... | Bortezomib Dexamethasone Pelareorep Pembrolizumab | 18 Years - | University of Southern California | |
| Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma. | NCT02086942 | Multiple Myelom... | Bortezomib cyclophosphamid... Dexamethasone | 18 Years - | Jinling Hospital, China | |
| Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | NCT04751877 | Multiple Myelom... Myeloma | Isatuximab Lenalidomide Bortezomib Dexamethasone | 65 Years - 79 Years | Poitiers University Hospital | |
| Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia | NCT00832234 | Waldenstroms Ma... | Bortezomib, Dex... | 18 Years - | Stichting European Myeloma Network | |
| Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma | NCT00334438 | Lymphoma | rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri... | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | NCT00439361 | Hodgkin Lymphom... Lymphoma | Bortezomib Carboplatin Etoposide Ifosfamide Mesna | 16 Years - | M.D. Anderson Cancer Center | |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04975997 | Multiple Myelom... | Dexamethasone Daratumumab Bortezomib Iberdomide Iberdomide Iberdomide | 18 Years - | Celgene | |
| Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma | NCT00458913 | Malignant Mesot... | bortezomib cisplatin | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma | NCT03016988 | Mantle Cell Lym... | Bortezomib Fludarabine Cytarabine | 18 Years - 75 Years | Fujian Medical University | |
| Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | NCT00379574 | Lymphoma, Large... Lymphoma, B-Cel... | Bortezomib Cyclophosphamid... Doxorubicin Vincristine Prednisolone Lenograstim | 15 Years - 70 Years | Asan Medical Center | |
| Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia | NCT00651781 | Acute Myeloid L... | Bortezomib | 18 Years - | PETHEMA Foundation | |
| Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia | NCT03591744 | Plasma Cell Leu... | Bortezomib Daratumumab Dexamethasone Lenalidomide Pegylated Lipos... | 18 Years - | City of Hope Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
